3D Tumor Spheroid Assay for Immune Cell Migration

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for studying immune cell migration and tumor cytotoxicity in cancer research often rely on two-dimensional models that do not accurately reflect the complexity of three-dimensional tumors, leading to inadequate understanding of immune cell infiltration and tumor immune evasion, which limits the effectiveness of immunotherapy across all cancer types and patients.

Innovation Solution

A method and labware system that allows for the investigation of therapeutic agents, such as immune cells or drugs, on tumor cells growing in three-dimensional spheroid conformation, enabling the detection of active migration and cytotoxicity in a single, high-throughput, easy-to-use system that mimics in vivo conditions by using a cell culture article with a porous membrane insert to simulate biological barriers like the blood-brain barrier.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If two-dimensional tumor cell systems are used to study immune cell migration and cytotoxicity, then the assay simplicity and ease of operation are improved, but the accuracy and reliability of the model in reflecting in vivo conditions deteriorates

Engineering Contradiction:
Improveassay simplicityVSAvoidmodel accuracy
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent transitions from traditional two-dimensional tumor cell monolayers to three-dimensional tumor spheroid models. This dimensional change allows immune cells to migrate through and interact with tumor cells in a more physiologically relevant manner, accurately reflecting the complex architecture and barriers of in vivo tumors while maintaining assay feasibility through standardized spheroid formation protocols

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

2Reliability

If three-dimensional tumor cell systems are used to study immune cell infiltration, then the model accuracy and reliability are improved, but the device complexity and assay difficulty increase

Engineering Contradiction:
Improvemodel accuracyVSAvoidassay complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The assay is segmented into distinct functional components: tumor spheroid formation in separate wells, immune cell preparation and loading into inserts, co-culture incubation, and readout measurements. This segmentation allows each step to be optimized and standardized independently, reducing overall assay complexity while maintaining the physiological relevance of the three-dimensional model

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses porous membrane inserts as an intermediary component to facilitate controlled interaction between immune cells and tumor spheroids. The inserts allow immune cells to migrate through a defined barrier toward the tumor spheroid, providing a standardized interface that simplifies the complex process of studying immune cell infiltration into three-dimensional tumor structures

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of operation

If traditional separate assays are used to study homing and cytotoxicity, then the ease of operation is improved, but the loss of time and productivity deteriorates

Engineering Contradiction:
Improveassay ease of useVSAvoidtesting time
Core Design Contradiction:
Ease of operationVSLoss of time

Solution Approach 1:

The patent merges previously separate homing assays and cytotoxicity assays into a single integrated co-culture system. Immune cells are co-cultured with tumor spheroids in the same well, allowing simultaneous assessment of both migration toward the tumor (homing) and direct killing of tumor cells (cytotoxicity) in one experiment, thereby reducing time and resource requirements

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a more in vivo-like testing model for immune cell and drug interactions with tumors, enhancing the understanding of tumor cytotoxicity and immune evasion, and identifying effective therapeutic agents that can cross biological barriers, thus improving the efficacy of cancer treatments.

Implementation Method 1

detecting active migration of the therapeutic agent from the insert into the cell culture article chamber

Methodology Applied
Scientific EffectActive migration:

Implementation Method 2

detecting infiltration of the therapeutic agent, such an immune cell, into the tumor cell spheroid

Methodology Applied
Scientific EffectInfiltration:

Implementation Method 3

detecting tumor cell response. In embodiments, tumor cell response may be tumor cell lysis

Methodology Applied
Scientific EffectTumor cell lysis:

Data Source

PatentEP3580333B1A high throughput 3D assay for immune cell and drug homing, migration and tumor cytotoxicity
Publication Date: 2021.04.21 CORNING INC
  • EP3580333B1 patent drawingFigure 1A~1C
  • EP3580333B1 patent drawingFigure 2
  • EP3580333B1 patent drawingFigure 3A~3B

AI summary

The present disclosure relates to methods for performing assays for active migration and cytotoxicity of a therapeutic agent towards tumor cells, e.g., immune cell and/or drug homing, migration, and tumor cytotoxicity. The methods are performed in labware that provide opportunities for a therapeutic agent, such as an immune cell or a drug, to migrate toward tumor cells, including tumor cells growing in a 3D spheroid conformation. The methods allow for, among other uses, the investigation of the effects of a therapeutic agent, such as immune cells or a drug, on tumor cells, and enable the investigation of homing, tumor cytotoxicity, and tumor immune evasion in a single, easy-to-use, high throughput system for more in vivo-like testing.